Biotech - Big Pharma Collaborations: Modified And Terminated Agreements, June 9-Aug. 18, 2005#

I. MODIFIED AGREEMENTS

Biotech Co.*
(Country;
Symbol)

Pharma Co.
(Country)

Change from original
agreement

Terms/Details (Date)

DOV
Pharmaceutical
Inc. (DOVP)

Merck & Co. Inc.

They amended 2004 deal covering clinical development of DOV 21,947 and DOV 216,303, following early trial data on 21,947

Certain early stage clinical trials for DOV 21,947 now will be undertaken by DOV; DOV would be reimbursed if Phase II results of the depression candidate are successful (8/8)

Karo Bio AB
(Sweden; SSE:
KARO)

Wyeth Pharmaceuticals

They extended a deal signed in 2001 for an additional year

They are working on new treatments for atherosclerosis by targeting the liver X receptor; terms were not disclosed (8/15)

Memory
Pharmaceuticals
Corp. (MEMY)

Hoffmann-La Roche Inc.

Memory reacquired the rights to the PDE4 inhibitors MEM 1414 and MEM 1917, which Roche stopped developing for Alzheimer's disease in April

Roche has an option to continue development of the drugs after Phase II trials; Roche also maintains exclusive rights to all other drug candidates from Memory's PDE4 inhibitor program (8/18)

Qiagen Nv
(the Netherlands;
QGEN)

Abbott Laboratories

Abbott got distribution rights to a number of PCR diagnostic tests under an extension to an existing deal

Abbott has nonexclusive distribution rights to certain Qiagen products; the PCR assays were developed by Artus GmbH, which Qiagen acquired (6/22)

Senetek plc
(OTC
BB:SNTKY)

Valeant Pharmaceuticals International

Valeant got expanded distribution rights for Kinetin and exclusive worldwide rights to Zeatin

Senetek will get minimum royalty payments of $37M through 2010 for the skincare product Kinetin (Kinerase), plus potential additional royalties (8/9)

Gilead
Sciences Inc.
(GILD)

Hoffmann-La Roche Inc.

Gilead is seeking to terminate a 1996 agreement on the influenza product Tamiflu

Gilead is alleging material breach of the agreement, and wants to regain all rights to the product held by Roche (6/23)

II. TERMINATED AGREEMENTS

Advancis
Pharmaceutical
Corp. (AVNC)

Par Pharmaceutical Corp.

Par terminated a deal covering Advancis' Amoxicillin Pulsys product

The move followed a failed trial in strep throat; Par may be entitled to a portion of some future revenues (8/4)

Notes:

^# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange.